BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in ...
Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –– ...
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
The disgraced film producer was diagnosed with leukaemia in November. Now his lawyer has confirmed that the 72-year-old was rushed to hospital after an "alarming blood test result". His lawyer, Imran ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that ...
Gazette staff from wire reports ...
Dana-Farber Cancer Institute researchers are leading three studies that yield new insights to help improve treatment for patients with acute myelogenous leukemia (AML). The research teams will present ...
Upadacitinib was superior to dupilumab for the treatment of atopic dermatitis in the head and neck, trunk, upper limbs, and lower limbs.